Table 2.
Efficacy of lenvatinib plus anti-PD-1 antibody in patients receiving surgery (n = 30).
| Response | RECIST Version 1.1 | mRECIST | ||
|---|---|---|---|---|
| INR | IIR | INR | IIR | |
| Objective response rate, % | 50.0 | 50.0 | 50.0 | 50.0 |
| 95% CI a | 31.3-68.7 | 31.3-68.7 | 31.3-68.7 | 31.3-68.7 |
| Complete response | 0 (0%) | 0 (0%) | 7 (23.3%) | 7 (23.3%) |
| Partial response | 15 (50.0%) | 15 (50.0%) | 8 (26.7%) | 8 (26.7%) |
| Stable disease | 15 (50.0%) | 15 (50.0%) | 15 (50.0%) | 15 (50.0%) |
IIR, Independent imaging review; INR, Investigator review; mRECIST, modified response evaluation criteria in solid tumors.
a
Calculated using the Clopper-Pearson method.